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Introduction
Osteogenesis imperfecta (OI) (McKusick 259420) type IV is a
dominantly inherited disorder characterized by normal or grey-
ish sclerae, mild to moderate deformity and variable stature.
Some infants have fractures and deformity at birth while others
have only mild to moderate femural bowing (1). Recently, cycli-
cal intravenous treatment with bisphosphonates has proven of
benefit to adults and children with OI (2-5).
A 2-day-old male infant was admitted because of humeral frac-
ture. He was born at term by spontaneous vaginal delivery af-
ter an uneventful pregnancy as the second child of unrelated
parents. The father and the brother are affected by OI type IV.
On admission, the infant had body lenght of 50 cm (50th cen-
tile), body weight 3080 g (50th centile). A skeletal series
showed multiple healing of bilateral ribs and right clavicola,
acute fracture of right humeral and deformed long bones. Hy-
pertelorism, wormian bones on the skull films and generalized
osteopenia were noted (Figure1A). Routinary laboratory data
showed normal values including serum calcium, phosphate
and alkaline phosphatase. He was breast fed but ate poorly
and cried irritably. Daily vitamin D 400 UI/day was prescribed.
Over the next few days fractures of femur bilaterally, left
humeral and right radius occurred. Protective splints for the ex-
tremites to stabilize the fracture have been performed and
foam pads and gel cushions were used to reduce the risk of
new fractures.
On the18th day of recovery a morphine analougus Fentanyl at
1 μg/kg/h ev was used for pain without clinical improvement.
Cyclic neridronate infusion 1 mg/kg for two consecutive days
was started from when he was 20 days old and every 3 months
thereafter. Serum calcium and urine calcium/creatinine have
been monitorized before and daily for one week after the first
two infusions showing always normal values. His feeding and
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Figure 1 - Anteroposterior radiographs of lower limbs (A) before and (B)
after neridronate treatment in an infant with osteogenesis imperfecta. 
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activity improved gradually after the first infusion. At present he
is 14 months old with age-appropriate growth and good psy-
chomotor development. No additional fractures occurred after
the first infusion. Radiography of lower limbs showed lessened
deformities and improvement in osteopenia (Figure 1B).
Dual-energy X ray absorptiometry (DEXA) Hologic QRR-4500
A) revealed lumbar spine bone mineral density (BMD L2-L4))
of 0.229 g/cm2 and bone mineral content (BMC L2-L4) of 0.63
g before treatment and of 0.311 g/cm2 and 3.96 g respectively
after forth infusion. 
Bisphosphonate treatment has been used with beneficial ef-
fect in a newborn infant by Chien et al. (6). The Author treat-
ed with cyclic pamidronate a 14 day old infant affected by se-
vere OI who presented a generalized seizure 5 days after the
first infusion associated with hypocalcaemia. Subclinical
hypocalcaemia was noted after the second infusion. A mild
drop in serum calcium from normal pre-treatment values,
without associated clinical symptoms, has been also reported
after pamidronate treatment in OI infants over two months of
age (3). 
Our case shows that treatment with neridronate does not seem
to affect calcium balance even in the newborn period that is
known “per se” to be at risk for hypocalcaemia.
Therefore neridronate can be considered a safety and effica-
cious drug also in newborn infants with severe OI, although it is
still unclear at present how long the treatment should be con-
tinued. 
References
1. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet. 2004;
363:1377-1385.
2. Glorieux FH, Bishop NJ, Plotin H, et al. Cyclic administration of
pamidronate in children with severe osteogenesis imperfecta. N
Engl J Med. 1998;339:947-952. 
3. Plotkin H, Rauch F, Bishop NJ, et al. Pamidronate treatment of se-
vere osteogenesis imperfecta in children under 3 years of age. J In-
herit Metab Dis. 2000;85:1846-1850.
4. Adami S, Gatti T, Colapietro F, et al. Intravenous neridronate in
adults with osteogenesis imperfecta. J Bone Miner Res. 2003;18:
126-130.
5. Gatti D, Antoniazzi F, Prizzi R, et al. Intravenous neridronate in
children with osteogenesis imperfecta: a randomized controlled
study. J Bone Miner Res. 2005;20:758-763. 
6. Chien YH, Chu SY, Hsu CC, Hwu WL. Pamidronate treatment of
severe osteogenesis imperfecta in a newborn infant. J Inherit Metab
Dis. 2002;25:593-595.
Clinical Cases in Mineral and Bone Metabolism 2006; 3(1): 84-85 85
Normocalcaemia during neridronate treatment of newborn infant with osteogenesis imperfecta
NORMOCALCAEMIA_D’Eufemia  13/06/2006  12.16  Pagina 85
